High-dose esomeprazole and amoxicillin dual therapy for first-line helicobacter pylori eradication: A proof of concept study

Annals of Gastroenterology

Volumn 28, Issue 4, 2015, Pages 448-451

  Zullo, Angelo ^a   Ridola, Lorenzo ^b   De Francesco, Vincenzo ^c   Gatta, Luigi ^d   Hassan, Cesare ^a   Alvaro, Domenico ^b   Bellesia, Annamaria ^c   de Nucci, Germana ^e   Manes, Gianpiero ^e  

^a NUOVO REGINA MARGHERITA HOSPITAL   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c Gastroenteroolgy Unit   (Italy)

^d Versilia Hospital   (Italy)

^e Sapienza University of Rome “Polo Pontino” Hospital ^*  (Italy)

Author keywords

Amoxicillin; Dual therapy; Esomeprazole; Helicobacter pylori infection

Indexed keywords

AMOXICILLIN; ESOMEPRAZOLE;

ADULT; ARTICLE; BACTERIAL CLEARANCE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; FOLLOW UP; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER INFECTION; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; TREATMENT DURATION; UREA BREATH TEST;

EID: 84943195078     PISSN: 11087471     EISSN: 17927463     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. McColl KE. Clinical practice. Helicobacter pylori infection. N Engl J Med 2010; 362:1597-1604.
2. Zullo A, Hassan C, Ridola L, et al. Gastric MALT lymphoma: old and new insights. Ann Gastroenterol 2014;27:27-33.
3. Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection - the Maastricht IV/Florence Consensus Report. Gut 2012;61:646-664.
4. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007;102:1808-1825.
5. Hunt RH, Xiao SD, Megraud F, et al. Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J Gastrointest Liver Dis 2011;20:299-304.
6. Asaka M, Kato M, Takahashi S, et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter 2010;15:1-20.
7. De Francesco V, Giorgio F, Hassan C, et al. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis 2010;19:409-414.
8. Megraud F, Coenen S, Versporten A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013;62:34-42.
9. De Francesco V, Ierardi E, Hassan C, et al. Helicobacter pylori therapy: present and future. World J Gastrointest Pharmacol Ther 2012;3:68-73.
10. Fiorini G, Zullo A, Gatta L, et al. Newer agents for Helicobacter pylori eradication. Clin Exp Gastroenterol 2012;5:109-112.
11. De Francesco V, Zullo A, Hassan C, et al. Mechanisms of Helicobacter pylori antibiotic resistance: an updated appraisal. World J Gastrointest Pathophysiol 2011;2:35-41.
12. van Zwet AA, Vandenbroucke-Grauls CM, Thijs JC, et al. Stable amoxicillin resistance in Helicobacter pylori. Lancet 1998;352:1595.
13. Dore MP, Osato MS, Realdi G, et al. Amoxycillin tolerance in Helicobacter pylori. J Antimicrob Chemother 1999;43:47-54.
14. Grayson ML, Eliopoulos GM, Ferraro MJ, et al. Eff ect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur J Clin Microbiol Infect Dis 1989;8:888-889.
15. Lambert JR. Pharmacology of the gastric mucosa: a rational approach to Helicobacter polytherapy. Gastroenterology 1996;111:521-523.
16. Goddard AF, Jessa MJ, Barrett DA, et al. Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. Gastroenterology 1996;111:358-367.
17. Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 2008;64:935-951.
18. Gatta L, Perna F, Figura N, et al. Antimicrobial activity of esomeprazole versus omeprazole against Helicobacter pylori. J Antimicrob Chemother 2003;51:439-442.
19. Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and metaanalysis of sequential therapy. BMJ 2013;347:f4587.
20. Bayerdorff er E, Miehlke S, Mannes GA, et al. Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology 1995;108:1412-1417.
21. Zullo A, Hassan C, Andriani A, et al. Eradication therapy for Helicobacter pylori in patients with gastric MALT-lymphoma: a pooled data analysis. Am J Gastroenterol 2009;104:1932-1937.
22. Furuta T, Shirai N, Kodaira M, et al. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Th er 2007;81:521-528.
23. Yang JC, Lin CJ, Wang HL, et al. High-dose dual therapy is superior to standard fi rst-line or rescue therapy for Helicobacter pylori Infection. Clin Gastroenterol Hepatol 2015;13:895-905.
24. Ince AT, Tozlu M, Baysal B, Şentürk H, Arıcı S, Özden A. Yields of dual therapy containing high-dose proton pump inhibitor in eradication of H. pylori positive dyspeptic patients. Hepatogastroenterology 2014;61:1454-1458.
25. Zullo A, De Francesco V, Hassan C, et al. Modifi ed sequential therapy regimens for Helicobacter pylori eradication: a systematic review. Dig Liver Dis 2013;45:18-22.
26. Attumi TA, Graham DY. High-dose extended-release lansoprazole (dexlansoprazole) and amoxicillin dual therapy for Helicobacter pylori infections. Helicobacter 2014;19:319-322.
27. Sánchez-Delgado J, García-Iglesias P, Castro-Fernández M, et al. High-dose, ten-day esomeprazole, amoxicillin and metronidazole triple therapy achieves high Helicobacter pylori eradication rates. Aliment Pharmacol Ther 2012;36:190-196.
28. Shirai N, Sugimoto M, Kodaira C, et al. Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy. Eur J Clin Pharmacol 2007;63:743-749.